focus -WSS

focus

author：comprehensive 2025-09-29 20:51:40 - browse：93414

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

The benefits and risks of Eli Lilly’s treatment for Alzheimer’s disease were confirmed in detailed scientific disclosures Monday, paving the way for its full approval but leaving physicians with lingering questions about the medicine’s impact on patients as a new era in Alzheimer’s therapy unfolds.

The drug, called donanemab, showed a 35% slowing of Alzheimer’s disease progression relative to placebo in a clinical trial that enrolled 1,700 patients with early-stage disease. Numerically, that’s a modest, 3.3-point improvement on a 144-point survey, called the Integrated Alzheimer’s Disease Rating Scale, or iADRS, that combines measures of cognition and function, such as driving, managing finances, or carrying on conversations.

There was a similar benefit when donanemab’s efficacy was assessed using a more common measure of cognition called the Clinical Dementia Rating-Sum of Boxes, or CDR-SB. On that scale, the Lilly drug showed a 36% slowing of cognitive decline relative to placebo, or 0.68 points on an 18-point scale.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Unique patient identifier: Experts argue the benefits, pitfalls

focus

WSS

Scientists find bacteria from stomach of ancient iceman

Prosecutors seek bail revocation for FTX founder Sam Bankman

Judge in Trump's Jan. 6 case gives attorneys 2 weeks to propose trial date

Cano Health’s bankruptcy is a warning for Medicare Advantage

The CDC's new social media misinformation war

Medical schools are missing the mark on artificial intelligence

knowledge

focus

hotspot

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Pope greeted like rockstar, appears revitalized at 'Catholic Woodstock' in Portugal

As demand for Covid shots wanes, Moderna seeks its next success

340B reform proposal comes out of Senate working group

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Johnson & Johnson sued for allegedly overpaying for workers' drugs

Cancer drug shortages should be causing more outrage

Texas Medical Board asked to define abortion emergency exception

Walensky prepares to leave CDC — and Congress — behind

A single Democrat is willing to weaken Medicare negotiation power

entertainment

California Joshua trees severely burned in massive wildfire

Medical mystery: When an infection after surgery isn’t what it seems

Readout LOUD: Venture capital, Gilead, and more M&A

Tuesday set an unofficial record for the hottest day on Earth. Wednesday may break it.

Special counsel alerts court to Trump’s social media post

Readout LOUD: Venture capital, Gilead, and more M&A

entertainment

focus

entertainment

hotspot